Wallace, D. J., Dörner, T., Bono, S. d., Benschop, R. J., Dow, E. R., Fantini, D., . . . Hoffman, R. W. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWallace, Daniel J., et al. Baricitinib-associated Changes in Global Gene Expression During a 24-week Phase II Clinical Systemic Lupus Erythematosus Trial Implicates a Mechanism of Action Through Multiple Immune-related Pathways. BMJ Publishing Group.
MLA (9th ed.) CitationWallace, Daniel J., et al. Baricitinib-associated Changes in Global Gene Expression During a 24-week Phase II Clinical Systemic Lupus Erythematosus Trial Implicates a Mechanism of Action Through Multiple Immune-related Pathways. BMJ Publishing Group.